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Background. The eﬀect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the regression of carotid IMT remains largely unknown.
The present study aimed to clarify whether sitagliptin, DPP-4 inhibitor, could regress carotid intima-media thickness (IMT) in
insulin-treated patients with type 2 diabetes mellitus (T2DM). Methods. This is an exploratory analysis of a randomized trial in
which we investigated the eﬀect of sitagliptin on the progression of carotid IMT in insulin-treated patients with T2DM. Here, we
compared the eﬃcacy of sitagliptin treatment on the number of patients who showed regression of carotid IMT of ≥0.10mm in a
post hoc analysis. Results. The percentages of the number of the patients who showed regression of mean-IMT-CCA (28.9% in the
sitagliptin group versus 16.4% in the conventional group, P= 0.022) and left max-IMT-CCA (43.0% in the sitagliptin group versus
26.2% in the conventional group, P= 0.007), but not right max-IMT-CCA, were higher in the sitagliptin treatment group compared
with those in the non-DPP-4 inhibitor treatment group. In multiple logistic regression analysis, sitagliptin treatment signiﬁcantly
achieved higher target attainment of mean-IMT-CCA ≥0.10mm and right and left max-IMT-CCA ≥0.10mm compared to
conventional treatment. Conclusions. Our data suggested that DPP-4 inhibitors were associated with the regression of
carotid atherosclerosis in insulin-treated T2DM patients. This study has been registered with the University Hospital
Medical Information Network Clinical Trials Registry (UMIN000007396).
1. Background
Type 2 diabetes mellitus (T2DM) is a risk factor for cardio-
vascular disease (CVD). Recent studies have cast doubt on
the beneﬁts of strict glycemic control on CVD in patients
with advanced atherosclerosis or longstanding T2DM [1–3].
Particularly, strict glycemic control using intensive insulin
therapy increases the risk of hypoglycemia [4] andweight gain
[5] which might reduce their beneﬁcial eﬀects. Therefore, a
reduction in insulin dose by stimulation of endogenous
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glucose responsive insulin secretion and increased insulin
sensitivity using oral hypoglycemic agents (OHA)may reduce
these adverse eﬀects of insulin therapy and be a promising
strategy to prevent the progression of atherosclerosis.
The carotid artery intima-media thickness (IMT) and its
progression are considered a marker of progression of
atherosclerosis. Recent studies demonstrated that add-on
therapy ofmetformin [6] or pioglitazone [7] to insulin therapy
did not slow down the progression of carotid IMT compared
with control group in patients withT2DM.On the other hand,
we recently reported that treatment with sitagliptin, a dipepti-
dyl peptidase-4 (DPP-4) inhibitor, attenuated the progression
of carotid IMT in insulin-treated patients with T2DM
comparedwith the conventional treatmentwithout increasing
the risk of hypoglycemia [8].
Previous studies demonstrated that several therapies for
cardiovascular risk factors including statin could regress
carotid IMT in patients with T2DM [9–12]. However, the
eﬀect of DPP-4 inhibitors on the regression of carotid IMT
remains largely unknown. In this study, we investigated
whether sitagliptin has beneﬁcial eﬀect on regressing carotid
IMT in a post hoc analysis while the original article focused
on investigating the eﬀects of sitagliptin on IMT progression.
2. Methods
2.1. Study Population.Weperformed a post hoc analysis from
the Sitagliptin Preventive Study of Intima-Media Thickness
Evaluation (SPIKE).The studydesign, inclusionandexclusion
criteria, study schedule, and measurements were described
in detail previously [8]. Brieﬂy, insulin-treated Japanese
T2DM patients, free of past history of apparent CVD, who
periodically attended the outpatient diabetes clinics at 12
centers across Japan were asked to participate in this study.
Randomization was performed using a dynamic allocation
method based on the number of times of insulin injection,
with/without pioglitazone, age, and gender. A total of 282
participants were randomly allocated to either the sitagliptin
group (n=142) or the conventional treatment group (using
drugs other than the DPP-4 inhibitor) (n= 140). Finally,
137 in the sitagliptin group and 137 in the conventional
treatment group were included in the full analysis set.
Each participant underwent ultrasonography of the carotid
arteries performed by expert sonographers at the start of
the study, and the procedure was repeated after 52 and
104 weeks as reported previously [8]. To avoid interreader
variability, all scans were electronically stored and emailed to
the central oﬃce (IMT Evaluation Committee, Osaka, Japan)
to be read by a single experienced reader blinded to the clinical
characteristics of the patients, in a random order, using
automated digital edge-detection software (Intimascope;
MediaCross, Tokyo, Japan). The software system averages
about 200 points of IMT values in the segment 2 cm proxi-
mal to the dilation of the carotid bulb (mean-IMT-CCA).
The greatest thicknesses of IMT, including plaque lesions
in the common carotid arteries (max-IMT-CCA), were also
measured separately. The reproducibility of IMT measure-
ment was very high as described previously [8]. Carotid
IMT regression was deﬁned as a decrease of ≥0.10mm in
mean-IMT-CCA, right max-IMT-CCA, and left max-IMT-
CCA at the end of the study from the baseline.
2.2. Statistical Analysis. Data were reported as mean± standard
deviation. The number and percentage of patients who achieved
the regression of IMT ≥0.10mm from the baseline at the end
of the study regression were presented using Fisher’s exact test.
Multiple logistic regression analysis was performed to compare
target attainment of IMT ≥0.10mm from the baseline at the
end of the study between the two groups. Classical atheroscle-
rotic risk factors basedon clinical judgmentwere included in the
model. Adjusted odds ratio (OR) estimates and Wald 95%
conﬁdence interval (CI) were calculated. Multivariate logistic
regressionmodelswere used to identify the factors for regression
of IMT ≥0.10mm from the baseline at the end of the study.
Classical atherosclerotic risk factors and changes in some of
them based on clinical judgment were included in the model.
All statistical tests were two-sided with 5% signiﬁcance level.
All analyses were performed using the SAS software version
9.4 (SAS Institute, Cary, NC).
3. Results
3.1. Baseline Clinical Characteristics and the Results of the
Original Article. As described previously [8], baseline clinical
characteristics including potential risk factors for carotid
atherosclerosis were comparable between the groups
(Table 1). The mean age was about 64 years, about 60% male,
and HbA1c was about 8% and the estimated diabetes
duration was about 17 years. Lipids and blood pressure of
study subjects were relatively well controlled. A total of 282
participants were randomly allocated to either the sitagliptin
group (n=142) or the conventional treatment group (using
drugs other than the DPP-4 inhibitor) (n= 140). Finally,
137 in the sitagliptin group and 137 in the conventional treat-
ment group were included in the full analysis set (Figure 1).
Changes in the mean (−0.053mm (−0.090, −0.016) (mean
change; 95% CI), P= 0.005, by one-sample t-test based on
mixed eﬀects model for repeated measures) and left maxi-
mum IMT (−0.087mm (−0.161, −0.014), P=0.021), but not
right maximum IMT (−0.033mm (−0.121, 0.054), P=0.45),
of the common carotid arteries were signiﬁcantly greater
after sitagliptin treatment compared with conventional
treatment (Table 2). Also, the improvement in HbA1c was
signiﬁcantly greater in the sitagliptin group than in the
conventional group (Table 2). On the other hand, there were
no diﬀerences between the two groups in other risk factors
such as BP, the lipid parameters at baseline, or their changes
during the observation period (Table 2).
3.2. The Percentage of Patients Achieving IMT Regression.
In this study, we compared the percentage of patients
who achieved a decrease of ≥0.10mm in mean-IMT-CCA
and right and left max-IMT-CCA at the end of the study.
The percentages of patients with regression of mean-IMT-
CCA (28.9% in the sitagliptin group versus 16.4% in the
conventional group, P= 0.022) and left max-IMT-CCA
(43.0% in the sitagliptin group versus 26.2% in the
conventional group, P=0.007) were higher in the sitagliptin
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treatment group compared with those in the conventional
treatment group. Also, the percentage in the right max-IMT-
CCA tended to be higher in the sitagliptin treatment group
compared with that in the conventional treatment group
(38.3% in the sitagliptin group versus 27.9% in the
conventional group, P= 0.10). Multiple logistic regression
analysis that included the treatment group, age, gender,
and baseline IMT (model 1) demonstrated that sitagliptin
treatment signiﬁcantly achieved higher target attainment of
mean-IMT ≥0.10mm and right and left max-IMT-CCA
Table 1: Clinical characteristics of patients of the two groups.
Parameters Sitagliptin group (n= 137) Conventional group (n= 137) P value
Age (years) 63.8± 9.7 63.6± 1.0 0.90
Gender (males) (%) 83 (61) 82 (60) 1.00
Body mass index 25.0± 4.3 25.0± 3.8 0.88
Current smoking 30 (22) 29 (21) 0.22
Duration of diabetes (years) 17.2± 8.5 17.3± 8.7 0.94
HbA1c at baseline (mmol/mol) 64.9± 11.9 63.9± 10.6 0.45
Systolic blood pressure (mmHg) 130± 16 132± 14 0.88
Total cholesterol at baseline (mmol/l) 5.02± 0.91 4.94± 0.86 0.50
HDL cholesterol at baseline (mmol/l) 1.46± 0.37 1.39± 0.38 0.14
Triglyceride at baseline (mmol/l) 1.13 (0.83, 1.55) 1.17 (0.90, 1.72) 0.22
eGFR (ml/min/1.73m2) 77.7± 21.2 79.7± 24.2 0.47
Mean IMT (mm) 0.84± 0.19 0.84± 0.21 0.81
Right maximum IMT (mm) 1.04± 0.29 1.06± 0.40 0.69
Left maximum IMT (mm) 1.10± 0.32 1.11± 0.41 0.87
Use of oral glucose-lowering agents
Metformin 49 (36) 48 (35) 1.00
Sulfonylurea 17 (12) 15 (11) 0.85
Glinides 2 (1) 19 (14) <0.001
Thiazolidinediones 13 (9) 11 (8) 0.83
α-Glucosidase inhibitor 41 (30) 42 (31) 1.00
Others
Angiotensin-converting enzyme inhibitors 8 (6) 4 (3) 0.59
Angiotensin II receptor blockers 53 (39) 69 (50) 0.07
Statins 66 (48) 63 (46) 0.81
Antiplatelet agents 29 (21) 30 (22) 1.00
Data are number (%) of patients or mean ± SD values.
IMT, intima-media thickness; eGFR, glomerular ﬁltration rate.
Excluded:
No visit after registration:
Consent withdrawn:
No visit after registration:
Excluded:
Registered patients=282
Sitagliptin group=142 patients Conventional group=140 patients
Full analysis set=137 patients Full analysis set=137 patients
Consent withdrawn:
3 patients
1
2
2
3
5 patients
Figure 1: Trial schema.
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≥0.10mm compared to conventional treatment (Table 3).
Similar ﬁndings were noted even in the adjusted models,
including model 2 (model 1 + body mass index + current
smoking); model 3 (model 2 + HbA1c, total cholesterol,
high-density lipoprotein cholesterol, triglyceride, and systolic
blood pressure); model 4 (model 3 + estimated glomerular
ﬁltration rate + angiotensin-converting enzyme/angiotensin
II receptor blocker, statin, and antiplatelets); and model 5
(model 4 + OHA).
3.3. Predictive Factors for Regression of IMT. Next, multivar-
iate logistic regression models were performed to identify
predictive factors for regression of mean-IMT-CCA and
right and left max-IMT-CCA. Sitagliptin treatment and
higher IMT at baseline were mainly associated with the
regression of carotid IMT (Table 4).
4. Discussion
Previous study demonstrated that aggressive lipid-lowering
therapies with a statin alone or statin and ezetimibe resulted
in regression of carotid IMT in patients with T2DM [9].
Theoretically, statin reversed carotid atherosclerosis through
reductions in the lipid, inﬂammation and oxidative stress,
and changes in tissue characteristic of plaque. With respect
to OHA, previous studies showed that pioglitazone treatment
led to the regression of carotid IMT in patient with T2DM
probably through a multitude of mechanisms, including
improvement in several metabolic factors and insulin
sensitivity, anti-inﬂammatory eﬀect, and direct actions on
the vascular cells [10, 11]. In addition, modulation in
postprandial hyperglycemia with repaglinide was reported
to be associated with the reduction in carotid IMT in patients
with T2DM [12]. However, ongoing background treatments
with thosedrugs atbaseline,not add-on therapies, didnothave
major impact on the regression of carotid IMT in this study
(Table 4). The eﬀects of these drugs may have already attrib-
uted to reduced carotid IMT although we did not collect the
Table 2: Eﬀects of sitagliptin on glucose metabolism, blood pressure lipid metabolism, and IMT.
Parameters Sitagliptin group (n= 137) Conventional group (n= 137) P value
HbA1c at baseline (mmol/mol)
104 weeks (change from baseline) −5.6± 11.4 −2.2± 10.0 0.004
Systolic blood pressure (mmHg)
104 weeks (change from baseline) 0± 19 3± 17 0.20
Total cholesterol at baseline (mmol/l)
104 weeks (% change from baseline) −2.7± 15.6 −1.8± 14.6 0.63
HDL cholesterol at baseline (mmol/l)
104 weeks (% change from baseline) 0.2± 15.2 −0.5± 14.7 0.74
Triglyceride at baseline (mmol/l)
104 weeks (% change from baseline) 0.0 (−25.1, 44.6) −1.6 (−24.6, 16.7) 0.35
Mean IMT (mm)
104 weeks (change from baseline) −0.03± 0.17 0.02± 0.14 0.008
Right maximum IMT
104 weeks (change from baseline) 0.00± 0.35 0.02± 0.37 0.67
Left maximum IMT
104 weeks (change from baseline) −0.06± 0.34 0.02± 0.29 0.033
Data are mean ± SD or median (range) values. Diﬀerences in parameters from baseline to 104 weeks between groups were analyzed by the Student t-test or
Wilcoxon’s rank sum test. IMT, intima-media thickness.
Table 3: Results of adjustment randomized comparisons.
Adjusted odds ratio (95% CI) P value
Mean intima-media thickness
Model 1 2.29 (1.17–4.47) 0.015
Model 2 2.27 (1.16–4.44) 0.016
Model 3 2.48 (1.24–4.93) 0.010
Model 4 2.60 (1.29–5.28) 0.008
Model 5 2.89 (1.34–6.24) 0.007
Right maximum intima-media thickness
Model 1 1.77 (1.00–3.13) 0.049
Model 2 1.78 (1.00–3.14) 0.049
Model 3 1.87 (1.04–3.34) 0.036
Model 4 1.88 (1.05–3.40) 0.035
Model 5 2.15 (1.12–4.14) 0.022
Left maximum intima-media thickness
Model 1 2.22 (1.25–3.92) 0.006
Model 2 2.24 (1.26–3.98) 0.006
Model 3 2.33 (1.28–4.22) 0.006
Model 4 2.43 (1.32–4.48) 0.004
Model 5 2.46 (1.28–4.73) 0.007
Multiple logistic regression analysis included the treatment group, age,
gender, and baseline IMT (model 1); model 1 plus body mass index
and current smoking (model 2); model 2 plus HbA1c, total cholesterol,
high-density lipoprotein cholesterol, triglyceride, and systolic blood
pressure (model 3); model 3 plus eGFR, use of angiotensin-converting
enzyme/angiotensin II receptor blocker, use of statin, and use of antiplatelets
(model 4); model 4 plus the use of oral hypoglycemic agents (model 5).
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data about the treatment periods. Furthermore, sitagliptin
treatment was still associated with and was an independent
predictive factor for the regression of carotid IMT even
considering several possible risk factors for atherosclerosis,
background therapies which may have antiatherosclerotic
eﬀects, and/or changes in metabolic parameters. Although
the exact mechanism by which DPP-4 inhibitors induce the
regression of carotid IMT remains uncertain at present, the
diﬀerences in carotid IMT progression could not be explained
by the diﬀerence in HbA1c as we discussed in the original
article [8]. The glucagon-like peptide-1 dependent and/or
independent eﬀect of DPP-4 inhibitors on the vascular wall
may attribute to reduced atherosclerosis [13–16].
There are several certain limitations. First, because the
limit of detection of IMT measured by ultrasound scanner
used in this study was <0.1mm, we deﬁned a decrease of
≥0.10mm in IMT as IMT regression in terms ofmeasurement
sensitivity in these exploratory post hoc analyses. There are
very few studies to investigate the eﬀect of drugs on IMT
regression. In a previous study, IMT regression was deﬁned
as a decrease of >0.020mm in mean IMT without reasonable
scientiﬁc grounds [12]. Whether these magnitudes of IMT
regression are clinically relevant still remained unclear.
Thus, it may be important to identify the magnitude of IMT
regression that is associated with the incidence of CVD.
In this regard, we are conducting a study to follow up
the incidence of CVD in the same cohort. We will
quantitatively assess the relationship between the incidence
of CVD and IMT regression. Second, these were exploratory
analyses with the concern of multiplicity of statistical testing.
These factors allow increased risk for false-negative and
false-positive signiﬁcance results. Thus, the ﬁndings should
be interpreted with caution.
5. Conclusions
In conclusion, our data suggested that DPP-4 inhibitors were
associated with the regression of carotid atherosclerosis in
insulin-treated T2DM patients free of apparent CVD.
Table 4: Results of multivariate logistic regression models for the regression of IMT of ≥0.10mm from baseline at the end of the study.
Factor
Mean IMT Right max IMT Left max IMT
Adjusted odds ratio
(95% CI)
P value
Adjusted odds ratio
(95% CI)
P value
Adjusted odds ratio
(95% CI)
P value
Age (1 year) 1.01 (0.95–1.06) 0.83 0.98 (0.94–1.02) 0.37 1.01 (0.97–1.06) 0.61
Gender (male/female) 1.99 (0.83–4.79) 0.12 0.67 (0.33–1.35) 0.26 1.02 (0.49–2.14) 0.95
Body mass index (1 kg/m2) 1.07 (0.95–1.20) 0.26 1.03 (0.94–1.13) 0.56 1.00 (0.91–1.10) 0.98
Estimated duration of diabetes (1 year) 1.02 (0.97–1.07) 0.42 0.99 (0.95–1.03) 0.65 1.02 (0.98–1.07) 0.26
Smoking (yes/no) 1.93 (0.67–5.52) 0.22 0.72 (0.30–1.74) 0.47 1.83 (0.77–4.35) 0.17
HbA1c (1mmol/l) 1.04 (0.69–1.56) 0.87 1.07 (0.76–1.51) 0.68 1.00 (0.70–1.44) 0.99
Systolic BP (1mmHg) 0.99 (0.96–1.02) 0.40 1.03 (1.01–1.06) 0.012 0.97 (0.94–0.99) 0.02
Total cholesterol (1mmol/l) 0.64 (0.35–1.18) 0.16 1.11 (0.69–1.79) 0.68 1.19 (0.72–1.95) 0.49
HDL cholesterol (1mmol/l) 0.44 (0.11–1.78) 0.25 1.19 (0.38–3.75) 0.76 0.69 (0.22–2.15) 0.52
Triglyceride (1mmol/l) 0.92 (0.58–1.44) 0.71 0.87 (0.59–1.29) 0.5 1.00 (0.72–1.38) 1.00
eGFR (1ml/min/1.73m2) 1.01 (0.99–1.03) 0.27 1.00 (0.98–1.01) 0.74 1.01 (0.99–1.03) 0.22
Baseline cIMT (0.01mm) 1.05 (1.03–1.08) <0.001 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) <0.001
Treatment group (sitagliptin
treatment/conventional treatment)
3.58 (1.60–7.99) 0.002 2.02 (1.07–3.84) 0.031 2.38 (1.23–4.58) 0.01
ACE/ARB (yes/no) 1.10 (0.50–2.45) 0.81 0.86 (0.45–1.68) 0.67 1.31 (0.66–2.63) 0.44
Statins (yes/no) 0.76 (0.33–1.74) 0.51 1.27 (0.64–2.49) 0.49 0.88 (0.44–1.76) 0.72
Antiplatelets (yes/no) 0.34 (0.12–0.96) 0.04 0.79 (0.35–1.79) 0.57 0.40 (0.17–0.97) 0.042
OHA (yes/no) 0.55 (0.26–1.18) 0.12 0.83 (0.43–1.58) 0.56 0.53 (0.27–1.04) 0.064
Changes in systolic BP at 104 weeks
from baseline (1mmHg)
1.00 (0.98–1.03) 0.94 1.02 (1.00–1.04) 0.079 0.99 (0.97–1.01) 0.45
Changes in HbA1c at 104 weeks from
baseline (1mmol/l)
1.25 (0.84–1.87) 0.27 1.13 (0.80–1.60) 0.49 0.91 (0.64–1.29) 0.59
Changes in total cholesterol at 104 weeks
from baseline (1mmol/l)
0.97 (0.94–1.00) 0.051 0.99 (0.97–1.02) 0.45 0.99 (0.96–1.01) 0.30
Changes in HDL cholesterol at 104 weeks
from baseline (1mmol/l)
1.00 (0.97–1.02) 0.76 1.01 (0.99–1.03) 0.33 1.01 (0.98–1.03) 0.59
Changes in triglyceride at 104 weeks from
baseline (1mmol/l)
1.00 (0.99–1.00) 0.39 1.00 (1.00–1.01) 0.22 1.00 (0.99–1.01) 0.85
Multivariate logistic regression models were used to identify the determination of the regression of IMT of ≥0.10mm from baseline at the end of the study.
ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blocker; BP, blood pressure; IMT, intima-media thickness; eGFR, glomerular ﬁltration rate;
OHA, oral hypoglycemic agents.
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